$VTRS

Campbell Paul sold $810K of VTRS

Campbell Paul (See Remarks) sold 50,076 shares of Viatris Inc (VTRS) at $16.17 ($0.81M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Campbell Paul
Published Jun 26, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VTRS
Neutral
medium confidence
Mentioned
$VTRS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VTRSNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price, and post-transaction holdings; it can marginally influence sentiment but does not change fundamentals by itself.

02

Market read

A scheduled insider sale under 10b5-1 is typically low-signal; any trading impact is likely limited unless part of a broader pattern.

03

What to watch

Traders may over-weight single insider sales; without context on prior insider activity, net selling trend, or concurrent fundamentals, the signal is weak.

Relevance 4/10Novelty 5/10Timing: after-hours/filing time (Form 4 filed 2026-06-26)

Background

The article is an SEC Form 4 insider transaction disclosure for Viatris (VTRS).

Company-level read

Ticker impact

$VTRSNeutralMedium confidence
Context

Viatris insider Campbell Paul sold 50,076 shares at $16.1711 via an open-market transaction under a 10b5-1 plan, per Form 4 filed June 26.

Expected impact

Likely limited near-term price impact; any effect should be small and fade unless followed by additional insider selling or fundamental news.

Evidence & confidence

The filing is a primary-source Form 4, but it specifies a pre-arranged 10b5-1 plan and the article provides no accompanying fundamental catalyst.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than a change in outlook.

Key entities

  • Viatris Inc

    Subject of the Form 4 insider transaction disclosure.

  • Campbell Paul

    Officer who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VTRSHigh

Q&A: Phentolamine for presbyopia: a non-miotic route to near vision

The FDA approved phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) for presbyopia in October 2026. The drug reduces pupil size via a sympatholytic mechanism, avoiding ciliary muscle engagement. Clinical trials showed 27.2% of patients gained near vision without losing distance vision. Experts discuss its unique mechanism and potential patient benefits compared to other presbyopia treatments.

$VTRSHighAI 8/10

Viatris Launches $36.50-Per-Share Tender Offer to Acquire Pacira BioSciences

Viatris (VTRS) has launched a tender offer to acquire Pacira BioSciences (PCRX) for $36.50 per share in cash. The offer, set to expire on November 16, 2026, is part of a merger agreement signed on October 8, 2026. Pacira's board has recommended shareholders accept the offer. The transaction is subject to regulatory approvals and shareholder participation.

$VTRSHighAI 9/10

Viatris launches tender offer for Pacira at $36.50 per share

Viatris Inc. (VTRS) subsidiary launched a tender offer to acquire Pacira BioSciences (PCRX) for $36.50 per share in cash. The offer expires November 16, 2026, and requires over 50% of shares to be tendered. Pacira's board recommends shareholders accept the offer. The merger does not need shareholder approval and is subject to antitrust clearance.